CLOs on the Move

Revision Optics

www.revisionoptics.com

 
ReVision Optics®, Inc., (RVO) is a privately held corporation headquartered in Southern California, USA. RVO`s main focus is developing unique optical solutions for the treatment of presbyopia. Fueled by a belief that no one should ever have to hold a menu out at arm`s length, the company developed the Raindrop® Near Vision Corneal Inlay, a unique patented refractive surgery solution. This inlay is designed to improve the near vision that has been lost by the eye`s natural aging process, called presbyopia. The Company is actively pursuing regulatory approvals and market opportunities for Raindrop® worldwide, and is committed to ridding the world of ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Kennedy Krieger Institute

Kennedy Krieger Institute, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Kennedy Krieger Institute, Inc. is based in Baltimore, MD. You can find more information on Kennedy Krieger Institute, Inc. at www.kennedykrieger.org

People

People, Pets and Vets is a doctor-led organization that partners with veterinarians to help them reach their full potential.

Alliance Home Health Care

Alliance Home Health Care and Adult Day Services is a company of integrity which prides itself on treating our clients and employees as family. It is our mission to insure that all our clients get the best possible care either through our services or by

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.

Global Healthcare Alliance

Global Healthcare Alliance is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Houston, TX. To find more information about Global Healthcare Alliance, please visit www.globalhca.com.